Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) Short Interest Update

Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) was the target of a large decline in short interest during the month of August. As of August 31st, there was short interest totaling 1,269 shares, a decline of 85.4% from the August 15th total of 8,695 shares. Approximately 0.0% of the shares of the company are short sold. Based on an average trading volume of 24,351 shares, the days-to-cover ratio is presently 0.1 days.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings raised shares of Oaktree Acquisition Corp. III Life Sciences from a “sell (d)” rating to a “sell (d+)” rating in a report on Thursday, August 13th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has an average rating of “Sell”.

Oaktree Acquisition Corp. III Life Sciences Stock Up 0.1%

Shares of NASDAQ OACC traded up $0.01 during midday trading on Friday, reaching $10.78. The company’s stock had a trading volume of 850 shares, compared to its average volume of 36,225. Oaktree Acquisition Corp. III Life Sciences has a fifty-two week low of $10.44 and a fifty-two week high of $10.88. The business’s 50 day moving average price is $10.75 and its two-hundred day moving average price is $10.70.

Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) last announced its quarterly earnings data on Wednesday, August 12th. The company reported $0.07 EPS for the quarter.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Rangeley Capital LLC boosted its stake in shares of Oaktree Acquisition Corp. III Life Sciences by 52.8% in the 1st quarter. Rangeley Capital LLC now owns 61,188 shares of the company’s stock valued at $647,000 after purchasing an additional 21,156 shares during the last quarter. Radcliffe Capital Management L.P. bought a new stake in Oaktree Acquisition Corp. III Life Sciences during the second quarter valued at $856,000. UBS Group AG grew its holdings in Oaktree Acquisition Corp. III Life Sciences by 987,110.0% during the 3rd quarter. UBS Group AG now owns 98,721 shares of the company’s stock worth $1,038,000 after acquiring an additional 98,711 shares during the period. DLD Asset Management LP grew its holdings in Oaktree Acquisition Corp. III Life Sciences by 0.9% during the 1st quarter. DLD Asset Management LP now owns 136,735 shares of the company’s stock worth $1,447,000 after acquiring an additional 1,200 shares during the period. Finally, Verition Fund Management LLC grew its holdings in Oaktree Acquisition Corp. III Life Sciences by 6.7% during the 3rd quarter. Verition Fund Management LLC now owns 161,740 shares of the company’s stock worth $1,693,000 after acquiring an additional 10,117 shares during the period.

About Oaktree Acquisition Corp. III Life Sciences

Oaktree Acquisition Corp. III Life Sciences (NASDAQ: OACC) is a special purpose acquisition company (“SPAC”) formed to pursue merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combinations with one or more businesses in the life sciences sector. Incorporated as a Cayman Islands exempted company, OACC is sponsored by Oaktree Capital Management, a global alternative investment firm with a longstanding track record in credit strategies and private equity.